Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lixte Biotechnology Holdings Inc.

4.83
-0.0450-0.92%
Post-market: 4.81-0.0200-0.41%19:48 EDT
Volume:81.04K
Turnover:390.72K
Market Cap:22.03M
PE:-3.35
High:4.94
Open:4.78
Low:4.42
Close:4.88
52wk High:5.14
52wk Low:0.6400
Shares:4.56M
Float Shares:2.87M
Volume Ratio:0.51
T/O Rate:2.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4423
EPS(LYR):-1.5943
ROE:-213.21%
ROA:-99.79%
PB:33.82
PE(LYR):-3.03

Loading ...

Company Profile

Company Name:
Lixte Biotechnology Holdings Inc.
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
2
Office Location:
680 East Colorado Boulevard,Suite 180,Pasadena,California,United States
Zip Code:
91101
Fax:
631 982 5050
Introduction:
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Directors

Name
Position
Geordan PursGlove
Chief Executive Officer and Chairman of the Board
Bas van der Baan
Chief Scientific Officer,President and Director
Jason Sawyer
Independent Director
Michael Holloway
Independent Director
Regina Brown
Director
René Bernards
Director

Shareholders

Name
Position
Geordan PursGlove
Chief Executive Officer and Chairman of the Board
Robert N. Weingarten
Vice President and Chief Financial Officer, Secretary
Bas van der Baan
Chief Scientific Officer,President and Director